Volume : 12, Issue : 11, November – 2025

Title:

COMMON ADVERSE EFFECT OF DRUG USED TO TREAT TUBERCULOSIS

Authors :

Sakshi V. Palhade , Amruta Bawane , Dr. Swati P. Deshmukh

Abstract :

One of the oldest known diseases to afflict humans, tuberculosis (TB) is a leading cause of death globally and is brought on by bacteria belonging to the Mycobacterium tuberculosis complex.
According to the WHO, tuberculosis is the second leading cause of death worldwide after HIV/AIDS, and it remains a serious threat to human health. The poor socioeconomic segment of the population and the marginalized segments of the community are particularly susceptible to tuberculosis. The national objective of India’s National Strategic Plan (2017–2025) is to eradicate tuberculosis by 2025. It calls for a greater knowledge and comprehension of tuberculosis. The introduction to disease, epidemiology, type of tuberculosis, pathogenesis, adverse drug reaction of drug and how to overcome them have all been covered in this review article.
The diagnostic methodology for PTB and EPTB, as well as a wealth of specific information about diagnostic modalities, have been explained. The treatment plans for drug-resistant, adverse drug reaction, and nutritional support , along with the latest medications suggested for multidrug-resistant tuberculosis. As a real attempt to assist eradicate tuberculosis from the planet in the near future, this review article was created following a thorough literature study with the goal of improving knowledge and raising awareness of the disease and adverse drug reaction.
Keywords: Tuberculosis pathogenesis, Tuberculosis diagnosis, Tuberculosis treatment, DOTS

Cite This Article:

Please cite this article in press Sakshi V. Palhade et al., Common Adverse Effect Of Drug Used To Treat Tuberculosis, Indo Am. J. P. Sci, 2025; 12(11).

REFERENCES:

1. Bansal R, Sharma D, Singh R. Tuberculosis and its treatment: an overview. Mini reviews in medicinal chemistry. 2018 Jan 1;18(1):58-71.
2. Peters DE, Ichipi-Ifukor RN. Effect of rifampicin on the lipid profile of albino rats. Journal of Applied Sciences and Environmental Management. 2013 Jul 9;17(1):133-7.
3. Jamil SM, Oren E, Garrison GW, Srikanth S, Lewinsohn DM, Wilson KC, Thomson CC. Diagnosis of tuberculosis in adults and children. Annals of the American Thoracic Society. 2017 Feb;14(2):275-8.
4. Golden MP, Vikram HR. Extrapulmonary tuberculosis: an overview. American family physician. 2005 Nov 1;72(9):1761-8.
5. Boumerdassi H, Djouadi LN, Hambli A, Fardeau ML, Ouzari HI, Nateche F. Physicochemical and microbiological water quality assessment of a Northwestern Algerian dam: detection of ichtyopathogenic bacteria. Polish Journal of Microbiology. 2023 Jun 14;72(2):187.
6. Boumerdassi H, Djouadi LN, Hambli A, Fardeau ML, Ouzari HI, Nateche F. Physicochemical and microbiological water quality assessment of a Northwestern Algerian dam: detection of ichtyopathogenic bacteria. Polish Journal of Microbiology. 2023 Jun 14;72(2):187.
7. Bhardwaj AK, Kumar D, Raina SK, Sharma S, Chander V. Assessment of extra pulmonary tuberculosis (EPTB) cases from selected tuberculosis units (TUs) of Himachal Pradesh, India. Int. J. Health. 2015;3:29-33..
8. World Health Organization, World Health Organization Staff. Global tuberculosis report 2013. World health organization; 2013.
9. Kamboj A, Lause M, Kamboj K. The problem of tuberculosis: myths, stigma, and mimics. InTuberculosis: Integrated Studies for a Complex Disease 2023 Apr 1 (pp. 1047-1062). Cham: Springer International Publishing
10. Shrivastava AK, Brahmachari S, Pathak P, Kumar R, Sainia T, Patel U, Mandil A. Clinico- epidemiological profile of extra-pulmonary tuberculosis in Central India. Int J Med Res Rev. 2015 Mar 31;3
11. World Health Organization, World Health Organization Staff. Global tuberculosis report 2013. World health organization; 2013.
12. Mohapatra PR, Janmeja AK. Tuberculous lymphadenitis. J Assoc Physicians India. 2009 Aug 1;57(6):585-90.
13. Vorster MJ, Allwood BW, Diacon AH, Koegelenberg CF. Tuberculous pleural effusions: advances and controversies. Journal of thoracic disease. 2015 Jun;7(6):981.
14. KUMAR DN. A CRITICAL REVIEW ON TUBERCULOSIS WITH ITS DIAGNOSIS AND TREATMENT.
15. Abraham P, Mistry FP. Tuberculosis of the gastrointestinal tract. Ind J Tuberculosis. 1992;39:251-7.
16. Crowley LV. An introduction to human disease: pathology and pathophysiology correlations. Jones & Bartlett Publishers; 2013.
17. Peters DE, Ichipi-Ifukor RN. Effect of rifampicin on the lipid profile of albino rats. Journal of Applied Sciences and Environmental Management. 2013 Jul 9;17(1):133-7.
18. Anand AC, Seth AK, Paul M, Puri P. Risk factors of hepatotoxicity during anti-tuberculosis treatment. Medical Journal Armed Forces India. 2006 Jan 1;62(1):45-9.
19. Parthasarathy R, Sarma GR, Janardhanam B, Ramachandran P, Santha T, Sivasubramanian S, Somasundaram PR, Tripathy SP. Hepatic toxicity in South Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamide. Tubercle. 1986 Jun 1;67(2):99-108.
20. Purohit SD, Gupta PR, Sharma TN, Gupta DN, Chawla MP. Rifampicin and hepatic toxicity. Indian J Tuberc. 1983;30:107-9.
21. Blumberg, H.M., Burman, W.J., Chaisson, R.E. and Daley, C.L., 2003. American thoracic society/centers for disease control and prevention/infectious diseases society of America: treatment of tuberculosis. American journal of respiratory and critical care medicine, 167(4), p.603.
22. Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampin: a meta- analysis. Chest. 1991 Feb 1;99(2):465-71.
23. Pande JN, Singh SP, Khilnani GC, Khilnani S, Tandon R. Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study. Thorax. 1996 Feb 1;51(2):132-6.
24. Baghaei P, Tabarsi P, Chitsaz E, Saleh M, Marjani M, Shemirani S, Pooramiri MV, Kazempour M, Farnia P, Fahimi F, Mansouri D. Incidence, clinical and epidemiological risk factors, and outcome of drug-induced hepatitis due to antituberculous agents in new tuberculosis cases. American journal of therapeutics. 2010 Jan 1;17(1):17-22.
25. Lee A M, Mennone J Z, Jones R C, Paul W S. Risk factors for hepatotoxicity associated with rifampicin and pyrazinamide for the treatment of latent tuberculosis infection: experience from three public health tuberculosis clinics. The International Journal of Tuberculosis and Lung Disease. 2002 Nov 1;6(11):995-1000.
26. Durand F, Bernuau J, Pessayre D, Samuel D, Belaiche J, Degott C, Bismuth H, Belghiti J, Erlinger S, Rueff B, Benhamou JP. Deleterious influence of pyrazinamide on the outcome of patients with fulminant or subfulminant liver failure during antituberculous treatment including isoniazid. Hepatology. 1995 Apr 1;21(4):929-32.
27. Kumar R, Shalimar, Bhatia V, Khanal S, Sreenivas V, Gupta SD, Panda SK, Acharya SK. Antituberculosis therapy–induced acute liver failure: magnitude, profile, prognosis, and predictors of outcome. Hepatology. 2010 May;51(5):1665-74.
28. Bertino Jr J, Fish D. The safety profile of the fluoroquinolones. Clinical therapeutics. 2000 Jul 1;22(7):798-817.
29. Rossouw JE, Saunders SJ. Hepatic complications of antituberculous therapy. QJM: An International Journal of Medicine. 1975 Jan 1;44(1):1-6.
30. Silva DR, Dalcolmo M, Tiberi S, Arbex MA, Munoz-Torrico M, Duarte R, D’Ambrosio L, Visca D, Rendon A, Gaga M, Zumla A. New and repurposed drugs to treat multidrug-and extensively drug-resistant tuberculosis. Jornal Brasileiro de Pneumologia. 2018 Mar;44:153- 60.
31. Chhetri AK, Saha A, Verma SC, Palaian S, Mishra P, Shankar PR. A study of adverse drug reactions caused by first line anti-tubercular drugs used in Directly Observed Treatment, Short course (DOTS) therapy in western Nepal, Pokhara. JPMA. 2008;58(10):531-6.
32. Koju D, Rao BS, Shrestha B, Shakya R, Makaju R. Occurrence of side effects from anti- tuberculosis drugs in urban Nepalese population under DOTS treatment. Kathmandu university journal of science, engineering and technology. 2005 Sep 30;1(1).
33. Girling DJ. Adverse effects of antitubereulosis drugs. Drugs. 1982 Jan;23(1):56-74.
34. Maqusood M, Khan FA, Swaroop A. A Study on Incidence of Adverse Drug Reaction of Anti-Tubercular Drugs in New Cases of Pulmonary Tuberculosis in a Tertiary Care Teaching Hospital. Int J Med Res Prof. 2016;2(3):53-6.
35. Prasad R, Garg R, Verma SK. Isoniazid-and ethambutol-induced psychosis. Annals of Thoracic Medicine. 2008 Oct 1;3(4):149-51.
36. Mandel W, Cohn ML, Russell WJ, Middlebrook G. Serum isoniazid levels and catalase activities of tubercle bacilli from isoniazid-treated patients.
37. Jackson SL. Psychosis due to isoniazid. British Medical Journal. 1957 Sep 28;2(5047):743.
38. Thundiyil JG, Kearney TE, Olson KR. Evolving epidemiology of drug-induced seizures reported to a Poison Control Center System. Journal of medical toxicology. 2007 Mar;3(1):15- 9.
39. Kass JS, Shandera WX. Nervous system effects of antituberculosis therapy. CNS drugs. 2010 Aug;24(8):655-67.
40. RE C. Ocular manifestation of ethambutol. Arch Ophthalmol. 1962;67:566-71.
41. TSAI RK, LEE YH. Reversibility of ethambutol optic neuropathy. Journal of ocular pharmacology and therapeutics. 1997 Oct;13(5):473-7.
42. Leibold JE. The ocular toxicity of ethambutol and its relation to dose. Annals of the New York Academy of Sciences. 1966 Apr;135(2):904-9.
43. Citron KM, Thomas GO. Ocular toxicity from ethambutol. Thorax. 1986 Oct;41(10):737.
44. Tang S, Yao L, Hao X, Zhang X, Liu G, Liu X, Wu M, Zen L, Sun H, Liu Y, Gu J. Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China. European Respiratory Journal. 2014 Dec 31;45(1):161-70.
45. Moore RD, Smith CR, Lietman PS. Risk factors for the development of auditory toxicity in patients receiving aminoglycosides. Journal of Infectious Diseases. 1984 Jan 1;149(1):23- 30.
46. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, Fujiwara P, Grzemska M, Hopewell PC, Iseman MD, Jasmer RM. the infectious diseases society. American thoracic society/centers for disease control and prevention/infectious diseases society of America: treatment of tuberculosis. Am J Respir Crit Care Med. 2003 Feb 15;167(4):603-62.
47. Huaman MA, Sterling TR. Treatment of latent tuberculosis infection–An Update. Clinics in chest medicine. 2019 Dec;40(4):839.
48. Ross JM, Badje A, Rangaka MX, Walker AS, Shapiro AE, Thomas KK, Anglaret X, Eholie S, Gabillard D, Boulle A, Maartens G. Isoniazid preventive therapy plus antiretroviral therapy for the prevention of tuberculosis: a systematic review and meta-analysis of individual participant data. The Lancet HIV. 2021 Jan 1;8(1):e8-15.
49. Lanzafame M, Vento S. Mini-review: Silico-tuberculosis. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases. 2021 May 1;23:100218.
50. Mamani M, Majzoobi MM, Torabian S, Mihan R, Alizadeh K. Latent and active tuberculosis: evaluation of injecting drug users. Iranian Red Crescent Medical Journal. 2013 Sep 5;15(9):775.
51. Daley CL, Iaccarino JM, Lange C, Cambau E, Wallace Jr RJ, Andrejak C, Böttger EC, Brozek J, Griffith DE, Guglielmetti L, Huitt GA. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Clinical Infectious Diseases. 2020 Aug 14;71(4):e1-36.
52. Chakraborty S, Rhee KY. Tuberculosis drug development: history and evolution of the mechanism-based paradigm. Cold Spring Harbor perspectives in medicine. 2015 Aug 1;5(8):a021147.
53. Ghodousi A, Tagliani E, Karunaratne E, Niemann S, Perera J, Köser CU, Cirillo DM. Isoniazid resistance in Mycobacterium tuberculosis is a heterogeneous phenotype composed of overlapping MIC distributions with different underlying resistance mechanisms. Antimicrobial agents and chemotherapy. 2019 Jul;63(7):10-128.
54. Liu L, Jiang F, Chen L, Zhao B, Dong J, Sun L, Zhu Y, Liu B, Zhou Y, Yang J, Zhao Y. The impact of combined gene mutations in inhA and ahpC genes on high levels of isoniazid resistance amongst katG non-315 in multidrug-resistant tuberculosis isolates from China. Emerging Microbes & Infections. 2018 Dec 1;7(1):1-0.Erwin ER, Addison AP, John SF, Olaleye OA, Rosell RC. Pharmacokinetics of isoniazid: the good, the bad, and the alternatives. Tuberculosis. 2019 May 1;116:S66-70.
55. Chakraborty S, Rhee KY. Tuberculosis drug development: history and evolution of the mechanism-based paradigm. Cold Spring Harbor perspectives in medicine. 2015 Aug1;5(8):a021147.
56. Ghodousi A, Tagliani E, Karunaratne E, Niemann S, Perera J, Köser CU, Cirillo DM. Isoniazid resistance in Mycobacterium tuberculosis is a heterogeneous phenotype composed of overlapping MIC distributions with different underlying resistance mechanisms.Antimicrobial agents and chemotherapy. 2019 Jul;63(7):10-128.
57. Liu L, Jiang F, Chen L, Zhao B, Dong J, Sun L, Zhu Y, Liu B, Zhou Y, Yang J, Zhao Y. The impact of combined gene mutations in inhA and ahpC genes on high levels of isoniazid resistance amongst katG non-315 in multidrug-resistant tuberculosis isolates from China. Emerging Microbes & Infections. 2018 Dec 1;7(1):1-0.
58. Ghodousi A, Tagliani E, Karunaratne E, Niemann S, Perera J, Köser CU, Cirillo DM. Isoniazid resistance in Mycobacterium tuberculosis is a heterogeneous phenotype composed of overlapping MIC distributions with different underlying resistance mechanisms.Antimicrobial agents and chemotherapy. 2019 Jul;63(7):10-128.
59. Stettner M, Steinberger D, Hartmann CJ, Pabst T, Konta L, Hartung HP, Kieseier BC. Isoniazid‐induced polyneuropathy in a tuberculosis patient–implication for individual risk stratification with gen Sotyping?. Brain and Behavior. 2015 Aug;5(8):e00326.
60. Desta Z, Soukhova NV, Flockhart DA. Inhibition of cytochrome P450 (CYP450)isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A. Antimicrobial agents and chemotherapy. 2001 Feb 1;45(2):382-92.
61. Shah R, Ankale P, Sinha K, Iyer A, Jayalakshmi TK. Isoniazid induced lupus presenting as oral mucosal ulcers with pancytopenia. Journal of Clinical and Diagnostic Research: JCDR. 2016 Oct 1;10(10):OD03.
62. Lee AY. Clinical use of anti-histone antibodies in idiopathic and drug-induced lupus. Immunological Medicine. 2022 Oct 2;45(4):180-5.
63. Constantinescu SM, Buysschaert B, Haufroid V, Broly F, Jadoul M, Morelle J. Chronic dialysis, NAT2 polymorphisms, and the risk of isoniazid-induced encephalopathy–case report and literature review. BMC nephrology. 2017 Sep 4;18(1):282.
64. Adithan C, Subathra A. NAT2 gene polymorphism: covert drug interaction causing phenytoin toxicity. Indian Journal of Medical Research. 2016 May 1;143(5):542-4.
65. Suzuki A, Yuen NA, Ilic K, Miller RT, Reese MJ, Brown HR, Ambroso JI, Falls JG, Hunt CM. Comedications alter drug-induced liver injury reporting frequency: Data mining in the WHO VigiBase™. Regulatory Toxicology and Pharmacology. 2015 Aug 1;72(3):481-90.
66. Yew WW. Clinically significant interactions with drugs used in the treatment of tuberculosis. Drug safety. 2002 Feb;25(2):111-3.
67. Durek C, Rüsch-Gerdes S, Jocham D, Böhle A. Sensitivity of BCG to modern antibiotics. European urology. 1999 Nov 1;37(Suppl. 1):21-5.
68. Iwamoto S, Suzuki T, Sutani AK, Kuraki TA, Isobe TA. A case of atypical drug-induced hypersensitivity syndrome caused by isoniazid. Kekkaku:[Tuberculosis]. 2012 Dec1;87(12):777-82.
69. Denholm JT, McBryde ES, Eisen DP, Penington JS, Chen C, Street AC. Adverse effects of isoniazid preventative therapy for latent tuberculosis infection: a prospective cohort study. Drug, healthcare and patient safety. 2014 Oct 20:145-9.
70. Stagg HR, Lipman MC, McHugh TD, Jenkins HE. Isoniazid-resistant tuberculosis: a cause for concern?. The International Journal of Tuberculosis and Lung Disease. 2017 Feb 1;21(2):129-39.
71. Sotgiu G, Centis R, D’ambrosio L, Migliori GB. Tuberculosis treatment and drug regimens. Cold Spring Harbor perspectives in medicine. 2015 May 1;5(5):a017822.
72. Berti E, Galli L, Venturini E, de Martini M, Chiappini E. Tuberculosis in childhood: a systematic review of national and international guidelines. BMC infectious diseases. 2014 Jan 8;14(Suppl 1):S3.
73. Golden MP, Vikram HR. Extrapulmonary tuberculosis: an overview. American family physician. 2005 Nov 1;72(9):1761-8.
74. Boumerdassi H, Djouadi LN, Hambli A, Fardeau ML, Ouzari HI, Nateche F.Physicochemical and microbiological water quality assessment of a Northwestern Algerian dam: detection of ichtyopathogenic bacteria. Polish Journal of Microbiology. 2023 Jun14;72(2):187.
75. Pham DD, Grégoire N, Couet W, Gueutin C, Fattal E, Tsapis N. Pulmonary delivery of pyrazinamide-loaded large porous particles. European Journal of Pharmaceutics and Biopharmaceutics. 2015 Aug 1;94:241-50.
76. https://www.nanavatimaxhospital.org/blogs/diet-for-tuberculosis